Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Shintaku

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockadeAntoni Ribas, Begoña Comin-Anduix, James S Economou, et al.
Genes, Chromosomes & Cancer|November 7, 2015
An infant with MLH3 variants, FOXG1-duplication and multiple, benign cranial and spinal tumors: A clinical exome sequencing studyRina Kansal, Xinmin Li, Joseph Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung CancerSiwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.
Nature|January 11, 2018
High response rate to PD-1 blockade in desmoplastic melanomasZeynep Eroglu, Jesse M Zaretsky, Siwen Hu-Lieskovan, et al.
Nature|November 28, 2014
PD-1 blockade induces responses by inhibiting adaptive immune resistancePaul C Tumeh, Christina L Harview, Jennifer H Yearley, et al.
Cancer Discovery|December 2, 2016
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsDaniel Sanghoon Shin, Jesse M Zaretsky, Helena Escuin-Ordinas, et al.
The New England Journal of Medicine|July 20, 2016
Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaJesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, et al.
Cancer Immunology Research|April 16, 2017
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLCPaul C Tumeh, Matthew D Hellmann, Omid Hamid, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockadeAntoni Ribas, Begoña Comin-Anduix, James S Economou, et al.
Genes, Chromosomes & Cancer|November 7, 2015
An infant with MLH3 variants, FOXG1-duplication and multiple, benign cranial and spinal tumors: A clinical exome sequencing studyRina Kansal, Xinmin Li, Joseph Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung CancerSiwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.
Nature|January 11, 2018
High response rate to PD-1 blockade in desmoplastic melanomasZeynep Eroglu, Jesse M Zaretsky, Siwen Hu-Lieskovan, et al.
Nature|November 28, 2014
PD-1 blockade induces responses by inhibiting adaptive immune resistancePaul C Tumeh, Christina L Harview, Jennifer H Yearley, et al.
Cancer Discovery|December 2, 2016
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsDaniel Sanghoon Shin, Jesse M Zaretsky, Helena Escuin-Ordinas, et al.
The New England Journal of Medicine|July 20, 2016
Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaJesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, et al.
Cancer Immunology Research|April 16, 2017
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLCPaul C Tumeh, Matthew D Hellmann, Omid Hamid, et al.
Pageof 3